Attached files

file filename
10-Q - 10-Q - TETRAPHASE PHARMACEUTICALS INCd918217d10q.htm
EX-10.1 - EXHIBIT 10.1 - TETRAPHASE PHARMACEUTICALS INCd918217dex101.htm
EX-31.1 - EXHIBIT 31.1 - TETRAPHASE PHARMACEUTICALS INCd918217dex311.htm
EX-31.2 - EXHIBIT 31.2 - TETRAPHASE PHARMACEUTICALS INCd918217dex312.htm
EX-10.3 - EX-10.3 - TETRAPHASE PHARMACEUTICALS INCd918217dex103.htm
EX-10.2 - EXHIBIT 10.2 - TETRAPHASE PHARMACEUTICALS INCd918217dex102.htm
EXCEL - IDEA: XBRL DOCUMENT - TETRAPHASE PHARMACEUTICALS INCFinancial_Report.xls
EX-32.1 - EXHIBIT 32.1 - TETRAPHASE PHARMACEUTICALS INCd918217dex321.htm

Exhibit 32.2

Certification of Chief Financial Officer

pursuant to 18 U.S.C. Section 1350, as adopted

pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the quarterly report on Form 10-Q of Tetraphase Pharmaceuticals, Inc. (the “Company”) for the period ended March 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), David C. Lubner, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

 

  (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

 

  (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 7, 2015

 

/s/ David C. Lubner
David C. Lubner
Chief Financial Officer